Leukotriene Antagonists
Selectively inhibit the cysteinyl leukotriene receptor, increased activity of which is involved in airway oedema and bronchial smooth muscle constriction.
| Property | Montelukast |
|---|---|
| Class | Leukotriene Antagonist |
| Uses | Asthma, allergic rhinitis |
| Route of Administration | PO |
| Dosing | 10mg daily |
| Absorption | 64% PO bioavailability |
| Distribution | t0.5 5 hours, >99% protein bound |
| Metabolism | Hepatic by CYP3A4 |
| Elimination | Predominantly faecal |
| Resp | Bronchodilatation |
References
- . Lexicomp. Montelukast: Drug information. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2017.